COVID-19 and neurological manifestations
K Forero, R Buqaileh, C Sunderman, W AbouAlaiwi - Brain Sciences, 2023 - mdpi.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a newly emerged
coronavirus, has sparked a global pandemic with its airborne transmission and ability to …
coronavirus, has sparked a global pandemic with its airborne transmission and ability to …
A Focused Review of the Initial Management of Patients with Acute Respiratory Distress Syndrome
A Motes, T Singh, N Vinan Vega, K Nugent - Journal of Clinical Medicine, 2023 - mdpi.com
At present, the management of patients with acute respiratory distress syndrome (ARDS)
largely focuses on ventilator settings to limit intrathoracic pressures by using low tidal …
largely focuses on ventilator settings to limit intrathoracic pressures by using low tidal …
ACE2 and a Traditional Chinese Medicine Formula NRICM101 Could Alleviate the Inflammation and Pathogenic Process of Acute Lung Injury
CH Lin, YJ Chen, MW Lin, HJ Chang, XR Yang, CS Lin - Medicina, 2023 - mdpi.com
COVID-19 is a highly transmittable respiratory illness caused by SARS-CoV-2, and acute
lung injury (ALI) is the major complication of COVID-19. The challenge in studying SARS …
lung injury (ALI) is the major complication of COVID-19. The challenge in studying SARS …
The Correlation of Serum Calpain 1 Activity and Concentrations of Interleukin 33 in COVID-19 Acute Respiratory Distress Syndrome
Acute respiratory distress syndrome (ARDS) is one of the most severe complications of the
COVID-19 disease. The role of IL-33 and calpain 1 was previously described in lung …
COVID-19 disease. The role of IL-33 and calpain 1 was previously described in lung …
Extracorporeal Photopheresis as a Possible Therapeutic Approach for Adults with Severe and Critical COVID-19 Non-Responsive to Standard Treatment: A Pilot …
Background: The optimal approach for adult patients hospitalized with severe and critical
coronavirus disease 2019 (COVID-19), non-responsive to antiviral and immunomodulatory …
coronavirus disease 2019 (COVID-19), non-responsive to antiviral and immunomodulatory …